ATJAUNINĀJUMS Hematoloģija / Onkoloģija 2024. gads
ESMO kongress 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Jūs izmantojat vecāku tīmekļa pārlūkprogrammas versiju, tāpēc dažas funkcijas var netikt parādītas pareizi.
MINIMĀLĀS prasības: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15–2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO tagad piedāvā sanāksmju resursus: +3.000 XNUMX slaidu un tīmekļa pārraides; tēzes un e-plakāti.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 uzlabo rPFS metastātisku kastrāciju rezistentu prostatas vēža slimniekiem, kuri nav lietojuši taksānus.
Reģistrējieties biļetēm vai kasēs
Norises vietas karte un viesnīcas apkārtnē
Minhene – Holiday Inn Munich – pilsētas centrs, Bavārija, Vācija Minhene – Holiday Inn Munich – pilsētas centrs, Bavārija, Vācija
Apmaksa